Biospring Partners ABZ Fund V, L.P.
Late investment period: first sale Aug 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $16.5M to $21.17M (Form D and SEC adviser filing)
- Stages
- Growth
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion.Inferred from the firm's website
02 · Initial check
$550K to $1.32M (estimated from fund size)
Estimated from Form D and SEC adviser filing
03 · Who to approach
Named on this fund's Form D
- MICHELLE DIPP, Manager of the General Partner of the Issuer
- Jennifer Lum, Managing Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideWe partner with technology-enabled, EBITDA-positive pharma services businesses driving innovation in manufacturing and clinical trial services.
We partner with technology-enabled, EBITDA-positive pharma services businesses driving innovation in manufacturing and clinical trial services
https://biospring.com/
06 · Sources
Last verified: Oct 28, 2026